`
`UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF COLORADO
`
`
`Civil Case No. 18-cv-00997-RM-KLM
`
`DUKE UNIVERSITY and
`ALLERGAN SALES, LLC,
`
`
`
`
`
`Plaintiffs,
`
`v.
`
`SANDOZ, INC.,
`
`Defendant and Counterclaim Plaintiff.
`
`FINAL JUDGMENT
`
`
`
`Pursuant to Fed. R. Civ. P. 58, Final Judgment is entered as follows:
`
`Plaintiffs Duke University (“Duke”) and Allergan Sales, LLC (“Allergan”) (collectively,
`
`“Plaintiffs”) alleged that Defendant Sandoz, Inc. (“Sandoz”) infringed Claim 30 of U.S. Patent No.
`
`9,579,270 (the “’270 patent”) under 35 U.S.C. §§ 271 (b) and (c) by selling its bimatoprost
`
`ophthalmic solution, 0.03% pursuant to its ANDA No. 202791 (“Sandoz Product”) in the United
`
`States, and that Sandoz’s infringement was willful.
`
`Sandoz alleged that Claim 30 of the ʼ270 patent is invalid for obviousness under 35 U.S.C.
`
`§ 103, invalid for lack of written description under 35 U.S.C. § 112, and invalid for lack of
`
`enablement under 35 U.S.C. § 112.
`
`On February 22, 2023, Sandoz stipulated that its sale and offer of sale, within the United
`
`States, of its bimatoprost ophthalmic solution, 0.03% pursuant to its ANDA No. 202791 (“Sandoz
`
`
`
`Case No. 1:18-cv-00997-RM-KLM Document 323 filed 05/22/23 USDC Colorado pg 2 of 3
`
`Product”), during the term of ’270 Patent constituted infringement of claim 30 of the ’270 Patent
`
`under 35 U.S.C. §§ 271 (b) and (c), unless that claim is found invalid. D.I. 252; see also D.I. 287.
`
`On March 27, 2023, the Court held a jury trial.
`
`On March 28, 2023, the Court granted Sandoz’s motion for judgment as a matter of law
`
`under FED. R. CIV. P. 50(a) as to Plaintiffs’ charge of willful infringement.
`
`On March 31, 2023, the jury returned its verdict.
`
`Pursuant to FED. R. CIV. P. 58(b), the Clerk of the Court enters judgment that:
`
`1.
`
`2.
`
`3.
`
`4.
`
`Claim 30 of the ʼ270 patent is not invalid for obviousness under 35 U.S.C. § 103.
`
`Claim 30 is not invalid for lack of written description under 35 U.S.C. § 112.
`
`Claim 30 is not invalid for lack of enablement under 35 U.S.C. § 112.
`
`Final judgment is entered against Sandoz on all of Plaintiffs’ claims, except that as
`
`to willful infringement, final judgment is entered against Plaintiffs.
`
`5.
`
`Damages are awarded to Duke in the amount of $1,227,172 and to Allergan in the
`
`amount of $37,772,828.
`
`6.
`
`Consistent with the parties’ agreement, Plaintiffs are awarded prejudgment interest
`
`at the weighted average prime rate for the period starting July 1, 2017 and ending on May 8, 2023
`
`at a rate of 4.56%, compounded quarterly. As of May 8, 2023, the prejudgment interest on
`
`Allergan’s share of the judgment is $11,444,942. As of May 8, 2023, the prejudgment interest on
`
`Duke’s share of the judgment is $371,826.
`
`7.
`
`Plaintiffs are awarded costs incurred in this action, to be taxed by the Clerk of the
`
`Court pursuant to Fed. R. Civ. P. 54(d)(1) and D. Colo. L.Civ.R. 54.1 and post-judgment interest
`
`pursuant to 28 U.S.C. § 1961.
`
`1
`
`
`
`Case No. 1:18-cv-00997-RM-KLM Document 323 filed 05/22/23 USDC Colorado pg 3 of 3
`
`8.
`
`The parties shall pay their own Colorado attorneys’ fees incurred in this case.
`
`Dated at Denver, Colorado this 22nd day of May, 2023.
`
`BY THE COURT:
`JEFFREY P. COLWELL, CLERK
`
` s/C. Pearson, Deputy Clerk
`
`
`
`
`
`2
`
`